|
|
|
International Clinical Trials
|
“Today, 47 million people live with dementia worldwide, more than the population of Spain. This number is projected to increase to more than 131 million by 2050, as populations age. Dementia also has a huge economic impact. The total estimated worldwide cost of dementia is US$818 billion, and it will become a trillion dollar disease by 2018” (1).
Because of the social impact of this chronic neurodegenerative disease, it has become a major target for new therapies and, together with Parkinson’s, accounts for approximately a third of all neurological trials initiated over the past five years (2). Despite this, the success of new medicines in the area is poor. At present, the only products on the market are Cholinesterase inhibitors and N-methyl-D-asparate (NMDA) antagonists, providing symptomatic therapy. Consequently, the drive for diseasemodifying treatments is huge, and, despite major setbacks for drugs in trials to date, in 2016, 51 Alzheimer’s trials were initiated compared to five in 2002 (3,4). Dominantly Inherited Alzheimer Network Trial (DIAN-TU) represents a new frontier for assessing the impact of disease-modifying drugs as it targets patients with a genetic predisposition and starts treatment prophylactically.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
PCI Announces Expansion of its Industry-Leading Cold Chain Infrastructure with Dedicated Minus 40 degrees C Facility
Philadelphia, USA – August 29, 2018 PCI Pharma Services (PCI), a full-service provider of specialist outsourced drug manufacturing, Clinical trial services, and commercial packaging to the global healthcare industry, is pleased to announce the completion of a purpose built -40°C storage and distribution facility at its North American Clinical Services Center of Excellence.
More info >> |
|
 |
White Papers |
 |
|
Advantages of Quantitative NMR for the Determination of Relative Response Factors
Novatia, LLC
Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >> |
|
 |
Industry Events |
 |
Outsourcing Clinical Trials Nordics 2018
30-31 October 2018, Copenhagen, Denmark
Following on from the success of the 2017 Outsourcing in
Clinical Trials Nordics conference, Arena International is pleased to announce
that the event will return for its 6th year in 2018.
The 2018 event welcomes biopharmaceutical and medical device
companies from across the Nordic region to share knowledge and challenges of
outsourcing and clinical operations.
More info >> |
|
|
